Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Index funds and ETFs each have roles; this note explains when index funds offer a simpler, cost-effective path for many investors.
26,830 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Circle Internet Group sparked a strong move in the market as investors welcomed a robust quarterly report. This artic...
A prominent fund has poured roughly $55 million into Dianthus as the stock climbs 350%. This article breaks down what...
Alta Fox quietly increases its XPEL exposure, lifting the stake to about 15.5% after a roughly $58 million purchase. ...
Crypto signals aren’t just about price. A single XRP on-chain metric recently jumped 920% in 30 days, triggering ques...
Investors chase the next big AI champion. This piece breaks down how a single AI stock could grow into a trillion-dol...
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
AI is reshaping markets faster than many investors expect. This no-brainer artificial intelligence (AI) stock story b...
A surprising move in the stock market drew attention to Super Micro Computer. This article breaks down the forces beh...
Perella Weinberg stock lags the broader market, even as a major fund just boosted its stake by about $15 million. Thi...
Hot IPOs and rapid meme stocks grab headlines, but durable income and resilience win long games. Here are three stock...
A new class-action alleges that Anthropic overstated Claude Max usage limits and the promised savings. The case could...